Distant Recurrence in Breast Cancer: Survival expectations and first choice of chemotherapy regimen

References

• Aisner J., Weinberg V., Perloff M., et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast. A CALGB study. J. Clin. Oncol. 1987; 5: 1523
   PubMed Web of Science ®Google Scholar
• Blumenschein G. R., Cardenas J. O., Freireich E. J., Gottlieb J. A. FAC chemotherapy for breast cancer. Proc. AACR & ASCO 1974; 15: 193
   Google Scholar
• Bonadonna G., Valagussa P. Chemotherapy of breast cancer. Current views and results. Int J. Radiat. Oncol. Biol. Phys. 1983; 9: 279
   PubMed Web of Science ®Google Scholar
• Brincker H. Problems associated with comparisons of response-defined subsets of patients in randomized trials. Treatment-related bias and response migration. Acta Oncol. 1987; 26: 425
   PubMed Web of Science ®Google Scholar
• Brincker H., Rose C., von der Maase H., Dombernowsky P. A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in metastatic breast cancer. Proc. ASCO 1984; 3: 113
   Google Scholar
• Broder L. E., Tormey D. C. Combination chemotherapy of carcinoma of the breast. Cancer Treat. Rev. 1974; 1: 183
   Google Scholar
• Bull J. M., Tormey D. C., Li S.H., et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649
   PubMed Web of Science ®Google Scholar
• Coates A., Gebski V., Stat M., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 1987; 317: 1490
   PubMed Web of Science ®Google Scholar
• Cooper R. G. Combination chemotherapy in hormone-resistant breast cancer. Proc. AACR & ASCO 1969; 10: 15
   Google Scholar
• Cummings F. J., Gelman R., Horton J. Comparison of CAF versus CMFP in metastatic breast cancer. Analysis of prognostic factors. J. Clin. Oncol. 1985; 3: 932
   PubMed Web of Science ®Google Scholar
• Fischer J., Rose C. J., Rubens R. D. Duration of complete response to chemotherapy in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 1982; 18: 747
   PubMedGoogle Scholar
• Gelber R. D., Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J. Clin. Oncol. 1986; 4: 1772
   PubMed Web of Science ®Google Scholar
• Greenspan E., Fieber M., Lesnick G., Edelman S. Response of advanced breast cancer to the combination of the antimetabolite, methotrexate, and the alkylating agent, thiotepa. J. Mt. Sinai Hosp. N. Y. 1963; 30: 246
   PubMedGoogle Scholar
• Karabali-Dalamaga S., Souhami R. L., O'Higgins N. J., Soumilas A., Clark C. G. Natural history and prognosis of recurrent breast cancer. Br. Med. J. 1978; 2: 730
   PubMedGoogle Scholar
• Muss H. B., White D. R., Richards F., et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial. Cancer 1978; 42: 2141
   PubMedGoogle Scholar
• Ross M. B., Buzdar A. U., Smith T.L., et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s and 1970s. Cancer 1985; 55: 341
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Carpenter J., Bartolucci A., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A Southeastern Cancer Study Goup project. Cancer 1977; 40: 625
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res. Treat. 1983; 3: 209
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Weinberg V. E., Leone L.A., et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am. J. Clin. Oncol. 1984; 7: 231
   PubMedGoogle Scholar